In 868 patients with stage II–III triple-negative breast cancer, adding carboplatin to anthracycline then taxane (neo)adjuvant chemotherapy improved event-free survival (5-year 82.3% vs 75.1%; HR 0.67) but raised grade ≥3 adverse events (74.7% vs 56.7%).
RCTn = 868
Kim et al. A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial